KDR and kidney cancer: The burden of kidney cancer rises with age, according to the time trend, but the decrease in death and disability loss in the years following 2016 points to the possible advantages of better treatment approaches, such as immune checkpoint inhibitors and tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor (VEGFR) (18), which have been shown to be effective in treating metastatic renal cell carcinoma.